Details of the Drug
General Information of Drug (ID: DMNRSYA)
Drug Name |
5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
5-Methoxytryptoline; 30439-19-1; CHEMBL6586; 1H-Pyrido(3,4-b)indole, 2,3,4,9-tetrahydro-5-methoxy-; 1H-Pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-5-methoxy-; 5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline; SCHEMBL4525164; CTK4G5204; DTXSID10184522; VPZWHBCLJCKHGZ-UHFFFAOYSA-N; AC1Q5856; AC1L5390; BDBM50136499; AKOS023631742; 1,2,3,4-Tetrahydro-5-methoxy-beta-carboline; 5-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 202.25 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||